Evidence map›Paper›PMID 38702074›Full record

ArticleFEBS open bio2024

PLGA nanocapsules as a delivery system for a recombinant LRP-based therapeutic.

Martin Bernert, Monique J Bignoux, Chandni Madhav, Sichumiso Gqeba, Tyrone C Otgaar, Gavin Morris, Stefan F T Weiss, Eloise Ferreira

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in FEBS open bio, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Martin BernertSchool of Molecular and Cell Biology, University of the Witwatersrand, Johannesburg, South Africa.
Monique J BignouxSchool of Molecular and Cell Biology, University of the Witwatersrand, Johannesburg, South Africa.
Chandni MadhavSchool of Molecular and Cell Biology, University of the Witwatersrand, Johannesburg, South Africa.
Sichumiso GqebaSchool of Molecular and Cell Biology, University of the Witwatersrand, Johannesburg, South Africa.
Tyrone C OtgaarSchool of Molecular and Cell Biology, University of the Witwatersrand, Johannesburg, South Africa.
Gavin MorrisSchool of Molecular and Cell Biology, University of the Witwatersrand, Johannesburg, South Africa.
Stefan F T WeissSchool of Molecular and Cell Biology, University of the Witwatersrand, Johannesburg, South Africa.ORCID 0000-0002-8721-5906
Eloise FerreiraSchool of Molecular and Cell Biology, University of the Witwatersrand, Johannesburg, South Africa.ORCID 0000-0001-5985-4885

Funding

Cancer Association of South AfricaTechnology and Innovation Agency, Department of Science and Innovation (DSI) South Africa
6 · The paper itself

Abstract

Telomerase activity is directly affected by the laminin receptor precursor (LRP) protein, a highly conserved nonintegrin transmembrane receptor, which has been shown to have therapeutic effects in ageing, and age-related diseases. Recently, it has been found that overexpression of LRP-FLAG, by plasmid transfection, leads to a significant increase in telomerase activity in cell culture models. This may indicate that upregulation of LRP can be used to treat various age-related diseases. However, transfection is not a viable treatment strategy for patients. Therefore, we present a nanoencapsulated protein-based drug synthesised using poly(lactic-co-glycolic acid) (PLGA) nanocapsules for delivery of the 37 kDa LRP protein therapeutic. PLGA nanocapsules were synthesised using the double emulsification-solvent evaporation technique. Different purification methods, including filtration and centrifugation, were tested to ensure that the nanocapsules were within the optimal size range, and the BCA assay was used to determine encapsulation efficiency. The completed drug was tested in a HEK-293 cell culture model, to investigate the effect on cell viability, LRP protein levels and telomerase activity. A significant increase in total LRP protein levels with a concomitant increase in cell viability and telomerase activity was observed. Due to the observed increase in telomerase activity, this approach could represent a safer alternative to plasmid transfection for the treatment of age-related diseases.

Indexed as

Cell SurvivalNanocapsulesPolylactic Acid-Polyglycolic Acid CopolymerDrug Delivery SystemsHEK293 CellsHumansLactic AcidPolyglycolic AcidReceptors, LamininRecombinant ProteinsTelomeraseLactic AcidNanocapsulesPolyglycolic AcidPolylactic Acid-Polyglycolic Acid CopolymerReceptors, LamininRecombinant ProteinsTelomeraseLRPnanoparticlePLGAtelomerasetherapeutic

Identifiers

PMID38702074
PMCPMC11216925

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.